In vitro study of the interaction between some fluoroquinolones and extracts of kola nitida seed

African Journal of Biotechnology

Volumn 5, Issue 19, 2006, Pages 1781-1784

  Ibezim, E C ^a   Esimone, C O ^a   Nnamani, P O ^a   Onyishi, I V ^a   Brown, S A ^b   Obodo, C E ^a  

^a UNIVERSITY OF NIGERIA   (Nigeria)

^b UNIVERSITY OF UYO   (Nigeria)

Author keywords

Ciprofloxacin; Interaction study; Kola nitida seed; Levofloxacin; Pefloxacin

Indexed keywords

CIPROFLOXACIN; KOLA NITIDA EXTRACT; LEVOFLOXACIN; PEFLOXACIN; PLANT EXTRACT; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIUM ISOLATE; COLA; CONTROLLED STUDY; DIFFUSION; DRUG POTENTIATION; ESCHERICHIA COLI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLANT SEED;

COLA NITIDA; ESCHERICHIA COLI;

EID: 33751224766     PISSN: 16845315     EISSN: 16845315     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. nd Edn, Enugu, Optimal Pubs, pp. 148-150.
2. Anozie K, Soladoye G (1984). Some species of Nigeria forest medicinal plants In: The state of medicinal plant research in Nigeria, Sofowora Edition, Ibadan University Press, Nigeria. p.15.
3. Brooks GF, Butol JS, Morse SA ((1998). In: Jawetz-Melnick and Adelbergs Medical Microbiology, Appleton and Lange New York. p.155.
4. Chambers HF, Jawetz E (1997). Principles of antimicrobial drug action-Sulphonamides, trimethoprim and quinolones. In: Basic and Clinical Pharmacology, Katzung BG (ed.) Stanford, Appleton and Lange, New York. pp. 119-120
5. th ed., American Public Health Association, Washington, D>C. pp. 233-296.
6. Cooke C, Sklar G, Nappin J (1996). Possible pharmacokinetic interactions with quinidine: ciprofloxacin or metronidazole? Ann. Pharmacother., 30: 364-366.
7. Davies S, Sparham PD, Spencer, R.C. (1987). Comparative activity of five fluoroquinolones against mycobacterium, J. Antimicrob. Chemother. 8: 1093-1102.
8. Drlica K (1999) Mechanisms of fluoroquinolone action, Curr. Opin. Microbiol. 2: 377-392.
9. Drlica K, Zhao R (1997). DNA gyrase/topoisomerase IV and the 4-quinolones, Microb. Mol. Bio. Rev. 61: 377-392.
10. Finch RG (1992). Clinical uses of antimicrobial drugs. In Pharmaceutical
11. th edn., Katzung, B. G. (ed) Stanford, Appleton and Lange, New York, pp. 812-826.
12. th edn., Blackwell Scientific Pub., New York. pp. 119-120.
13. Mandell GL, Sande MA (1960). Antimicrobial agents: sulfonamides, trimethoprim-sulfamethoxazole, quinolones and agents for urinary tract infection. In. The Pharmacological Basis of Therapeutics, Gilman AG, Rall TW, Nies AS, Taylor P, (eds.) Pergamon Press, New York. pp. 1047-1064.
14. Nehlig A, Daval JL, Debry G (1992). Caffeine and the central nervous system: Mechanisms of action, biochemical, metabolic and psychostimulant effects, Brain Res. Rev. 17: 139-170.
15. Odimgbe CI (1998). The phytochemical and antimicrobial properties of Kola nitida (Fanisterculiaceae). Unpublished B. Pharm project submitted to the Department of Pharmaceutical Chemistry, University of Nigeria, Nsukka. Pub., Oxford. pp. 134-153.
16. Vogel F (1995). A guide to the treatment of lower respiratory tract infections, Drugs. 50 (1): 62-72.
17. Weisser R, Asscher AW, Winpenny J (1966). In vitro reversal of antibiotic resistance of EDTA, Nature, 299: 1365-1366.
18. William HA, Grueberg NR (1986). Ciprofloxacin and co-trimoxazole in urinary tract infection. J. Antimicrob. Chemother. 18: 101-110.
19. Wise R, Lister D, McNulty CAM, Griggs D, Andrews JM (1986). The comparative pharmacokinetics of quinolones, J. Antimicrob. Chemother. 18 (Suppl. D) 71-81.